文献速递神经肿瘤

新诊断高级别胶质瘤(III和IV级)替莫唑胺治疗期间及治疗后的肿瘤体积变化

Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
PubMed 文献 · World Neurosurg · 2018-03-16

这项回顾性研究比较90例高级别胶质瘤患者辅助替莫唑胺治疗期间与停药后的肿瘤体积变化及总生存期。结果显示治疗期间肿瘤体积在总体人群、间变性星形细胞瘤组和胶质母细胞瘤组均显著下降(P≤0.001、P=0.042、P=0.005),中位总生存期为78.4周,与手术肿瘤切除率(r=0.241;P=0.04)和替莫唑胺总治疗周期数(r=0.631;P≤0.001)显著相关。结论认为延长替莫唑胺给药改善总生存期且未增加毒性。

要点

  • 辅助替莫唑胺治疗期间肿瘤体积在总体人群、间变性星形细胞瘤组和胶质母细胞瘤组均显著下降。
  • 中位总生存期为78.4周,与手术肿瘤切除率(r=0.241;P=0.04)和替莫唑胺总治疗周期数(r=0.631;P≤0.001)显著相关。
  • 延长替莫唑胺给药改善总生存期,未增加毒性。

核心结论

  • 在辅助替莫唑胺治疗期间,胶质母细胞瘤和间变性星形细胞瘤患者的肿瘤体积显著下降(P=0.042和P=0.005)。
  • 延长替莫唑胺给药改善总生存期,未增加毒性。

研究设计与样本

  • 这项回顾性研究旨在比较辅助替莫唑胺治疗期间与停药后的肿瘤体积变化及总生存期。
  • 共有90例患者接受了辅助替莫唑胺治疗。

主要发现

  • 比较替莫唑胺治疗期间与停药后的平均肿瘤体积变化,总体患者人群、间变性星形细胞瘤组和胶质母细胞瘤组在替莫唑胺治疗期间均观察到肿瘤体积显著下降(P≤0.001、P=0.042和P=0.005)。
  • 中位总生存期为78.4周,与手术肿瘤切除率显著相关(r=0.241;P=0.04)。
  • 中位总生存期为78.4周,与替莫唑胺总治疗周期数显著相关(r=0.631;P≤0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG). Several studies demonstrated that prolonged TMZ treatment increased survival for these patients. METHODS: This retrospective study aimed to compare changes in tumor volume during and after adjuvant TMZ treatment and overall survival (OS). RESULTS: There were 90 patients were administered adjuvant TMZ treatment. Comparing average tumor volume changes during TMZ treatment and after TMZ was stopped, a significant decrease in tumor volume was observed during TMZ treatment in the total patient population, the anaplastic astrocytoma (AA) group, and the glioblastoma multiforme (GBM) group (P ≤ 0.001, P = 0.042, and P = 0.005, respectively). Median overall survival was 78.4 weeks, which was significant regarding the surgical tumor resection rate (r = 0.241; P = 0.04) and total TMZ treatment cycles (r = 0.631; P ≤ 0.001). CONCLUSIONS: During adjuvant TMZ treatment, tumor volume decreased significantly (P = 0.042, and P = 0.005, respectively) in patients with GBM and AA. Prolonged TMZ administration improved OS, without increased toxicity.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wang HC, Lin YT, Lin WC, et al. Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV). World Neurosurg. 2018. PMID: 29555610. doi:10.1016/j.wneu.2018.03.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。